REGEN
Get REGENGet Now
LibraryToolsNotesBlogFAQ

SS-31 (Elamipretide) Side Effects and Safety

Reported SS-31 (Elamipretide) side effects, contraindications, and safety signals.

RE
Compiled from published research · Last updated 2026-07-24T00:00:00.000Z

Injection-Site Reactions Most Common

In the Barth syndrome trial program, injection-site reactions were the most commonly reported effect. Given the mixed results across other trial populations (heart failure, dry AMD, the broader mitochondrial-muscle trial), comprehensive safety data outside the approved rare-disease population remains limited.

Contraindications

  • pregnancy
  • known hypersensitivity

References

  1. Elamipretide in Barth syndrome (TAZPOWER) · 2024
  2. MMPOWER-3 elamipretide trial · 2020
All SS-31 (Elamipretide) sections

Thymosin Alpha-1

longevity & healthspanAgrade

A 28-amino-acid thymic peptide approved in 35+ countries as Zadaxin for immune support — but never FDA-approved in the United States.

Oxytocin

longevity & healthspanBgrade

A naturally occurring nonapeptide — FDA-approved as Pitocin for labor, and separately studied off-label (intranasal) for social bonding and stress research.

Humanin

longevity & healthspanCgrade

A mitochondrial-derived peptide discovered protecting neurons from Alzheimer's-linked toxicity — cell and rodent data only, no human trial exists.

Put the whole protocol
in one place.

Download nowGet Now